Study EV-103 Dose Escalation/Cohort A: 5y Follow-Up Of First-Line Enfortumab Vedotin + ...
Dr. Jonathan E. Rosenberg presented 5-year follow-up results of the EV-103 Study at the 2024 ESMO Congress, showing durable responses and meaningful survival outcomes with Enfortumab Vedotin (EV) + Pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC), with a median overall survival (OS) of 26 months and 41.5% of patients alive at 5 years.
Related Clinical Trials
Reference News
Dr. Jonathan E. Rosenberg presented 5-year follow-up results of the EV-103 Study at the 2024 ESMO Congress, showing durable responses and meaningful survival outcomes with Enfortumab Vedotin (EV) + Pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC), with a median overall survival (OS) of 26 months and 41.5% of patients alive at 5 years.